目的探讨孟鲁司特联合沙丁胺醇气雾剂治疗咳嗽变异性哮喘的疗效及对炎症因子的影响。方法选取2015年1月-2016年1月渭南市妇幼保健院儿科收治的咳嗽变异性哮喘患者120例,随机平均分配为观察组和对照组,对照组仅给予沙丁胺醇气雾剂治疗,观察组给予孟鲁司特联合沙丁胺醇气雾剂治疗。比较两组患者的临床疗效、患者肺功能恢复情况以及血清中炎症因子变化情况。结果治疗2个月后,对照组和观察组的有效率分别为73.3%和96.7%,观察组的有效率明显高于对照组,两组比较差异显著（P<0.05）。治疗前,两组患者FEV1、FEV1/FVC等肺功能相关的指标无统计学差异。治疗后,两组患者FEV1、FEV1/FVC均显著升高,与治疗前比较差异显著（P<0.05）；且观察组明显高于对照组,两组比较差异显著（P<0.05）。治疗前,两组患者血清IL-6、TNF-α水平无显著差异；治疗后,两组患者IL-6、TNF-α水平均显著降低,与治疗前比较差异显著（P<0.05）；且观察组患者治疗血清IL-6、TNF-α水平显著低于对照组（P<0.05）。结论采用孟鲁司特联合沙丁胺醇气雾剂治疗咳嗽变异性哮喘安全有效,可显著改善患者肺功能并降低炎症因子水平。

Objective To investigate the effect and influence on inflammatory factors of salbutamol aerosol combined with montelukast in treatment of cough variant asthma. Methods From Jan 2015 to Jan 2016, 120 cases of cough variant asthma in our hospital were selected as the subjects. They were randomly and equally divided into 2 groups:control group (n=60) were treated with salbutamol aerosol, and observation group were treated with salbutamol aerosol and montelukast. The clinical effects, the pulmonary function and the serum inflammatory factors were compared between the two groups. Results After 2 months of treatment, the effective rate of the control group and the observation group were 73.3% and 96.7% respectively, there was statistical differences between two groups (P < 0.05). The FEV1 and FEV1/FVC of both groups showed remarkable increase. The FEV1, FEV1/FVC of observation group were (2.21 ±0.17) L、(66.10 ±4.46)%, and the FEV1, FEV1/FVC of control group (1.82 ±0.11) L、 (52.48 ±3.34)%. The difference between two groups was statistically significant (P < 0.05). The IL-6 and TNF-α of both groups showed remarkable decrease. IL-6 and TNF-α in observation group were significantly lower than those of control group (14.58 ±2.90 vs. 20.87 ±3.26, P < 0.05; 0.59 ±0.12 vs. 0.97 ±0.15, P < 0.05). Conclusion The use of montelukast combined with salbutamol aerosol in the treatment of cough variant asthma was safe and effective, and could significantly improve pulmonary function and reduce inflammatory factor.